Hello,
Welcome to
- Arch Venture Partners is launching a new neuroscience mega biotech;
- Twin Health raised $140 million to treat metabolic conditions;
- Health insurers say that primary-care telehealth saves them money.
If you're new to this newsletter, sign up here. Comments, tips? Email me at lrosenbaum@insider.com or tweet @leah_rosenbaum. Let's get to it...
A new startup created by one of biotech's biggest VCs shows you either need to go big, or go home to treat brain disorders
- Arch Venture Partners launched
neuroscience startup Neumora on Thursday with $500 million in capital - It's part of the firm's push to make big investments in overlooked parts of the drug industry
- Neumora is the latest company to join the ranks of mega biotechs
See the 14-slide presentation that convinced ICONIQ and Sequoia to lead a $140 million investment in a startup focused on treating metabolic conditions
- Twin Health, a startup focused on metabolic conditions, raised $140 million in funding on Wednesday.
- ICONIQ led the round with Sequoia, which valued the company at $740 million.
- Twin Health uses a "digital twin" to treat metabolic conditions like obesity or diabetes.
Seeing a primary-care doctor online is getting easier, and health insurers say it's saving money
- Many insurers and
telehealth companies launched virtual primary-care programs amid the pandemic. - Some say they're starting to see promising results, like improved health outcomes and lower costs.
- They're betting that the future of primary care is virtual.
More stories we're reading:
- The WHO recommends the world's first malaria vaccine, saying the shots could 'save tens of thousands of young lives each year' (Insider)
- A Texas man has been sentenced to more than a year in prison for posting a COVID-19 hoax (CNN)
- Fauci rails against 'dark web people' harassing his wife and daughters with violent threats (Insider)
- A new brain implant helped relieve symptoms in a patient with severe depression (STAT)
-Leah